| Ytd | 227.50% | |
| 1y | 829.08% |
| Open | 13.15 | Prev Close | 13.10 | Low | 13.05 | High | 13.15 | Mkt Cap | 893.22M |
| Vol | 231.00 | Avg Vol | 1.26M | EPS | -0.78 | P/E | -16.79 | Forward P/E | N/A |
| Beta | 0.07 | Short Ratio | 15.74 | Inst. Own | 84.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 11.89 | 200-d Avg | 6.65 | 1yr Est | 10.00 |
CLYM News
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy
Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of it
Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging
U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive tr
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight
WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical
Climb Bio NASDAQ: CLYM outlined its clinical development strategy and upcoming data readouts during
WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical
WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, sup
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, sup
WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinica
Climb Bio, Inc. maintains a Buy rating, driven by budoprutug's strong phase 1b and long-term data in
WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinica
WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinica
Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S
Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2
WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) has been assigned an average recommendation of "Mod
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second ha
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) Director Ra Capital Management, L.P. acquired 101,4
WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical
PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial